Introduction
The field of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) experienced a paradigm shift after the introduction of drug-eluting stents (DES). More than a decade ago, PCI for CTO was hampered by high rates of restenosis and reocclusions with bare-metal stents and balloon angioplasty. 1 The introduction of DES resulted in an important reduction in target vessel revascularizations compared with bare-metal stents. 2, 3 Together with sophisticated innovations such as the retrograde approach, antegrade dissection re-entry, and hybrid algorithms, percutaneous CTO recanalization has become an important alternative to surgical revascularization. 4 Despite improved results with first-generation DES, concerns were raised after increased rates of very late stent thrombosis were observed. 5 Second-generation DES, with thin-strut designs and different antiproliferative drugs, showed comparable angiographic and clinical outcomes compared with first-generation DES in CTO. 6, 7 Chronic inflammation, hypersensitivity reactions on durable polymers, and late acquired stent strut malapposition were suggested as possible mechanisms of very late target vessel failure. 8, 9 The novel Orsiro hybrid ultrathin-strut sirolimus-eluting stent (SES) platform with biodegradable polymer (Biotronik, Berlin, Germany) was designed to overcome potential drawbacks of earlier generation DES. The cobalt-chromium stent consist of ultrathin struts (60 mm) covered with a silicon carbide layer to reduce passive ion release. The stent is coated with antiproliferative sirolimus embedded in biodegradable poly-L-lactic acid polymer, which gradually degrades in 12 to 24 months. In the BIOFLOW-II (Study of the Orsiro Drug Eluting Stent System) study, SES demonstrated comparable angiographic results with those obtained with thin-strut (81 mm) everolimus-eluting stents (EES) with durable polymer (Xience, Abbott Vascular, Santa Clara, California) in de novo lesions. 10 In this prospective, multicenter, single-blind trial, we investigated the angiographic outcomes of the new hybrid SES with biodegradable polymer compared with the EES with durable polymer in CTOs.
Methods

Study oversight
This investigator-initiated, prospective, randomized, single-blind, multicenter clinical trial was performed at two Belgian and six Dutch high-volume PCI centers. The Research and Development Department at St. Antonius Hospital (Nieuwegein, the Netherlands) was responsible for data collection and monitoring. Independent study monitors verified all source data on site. The Data and Safety Monitoring Board reviewed all cardiac and noncardiac adverse events. Two external experts not involved in the study adjudicated all clinical endpoints in a blinded fashion. The study investigators vouch for the accuracy and completeness of the data and the analyses. All Institutional Review Boards of the local centers approved the study. Written informed consent was obtained prior to the procedures. The study was performed in compliance with the standards of Good Clinical Practice (ICH/E6/R1) and the Declaration of Helsinki (Washington 2002). This trial is registered (NCT01516723). The rationale and design of this study were published previously. 11
Recruitment, enrolment, and randomization
Between February 2012 and June 2015, a total of 330 consecutive patients with successfully recanalized native total or chronic total coronary occlusions were randomized to the hybrid SES (Orsiro) or the EES (Xience Prime/Xpedition, Abbott Vascular) (11) .
Patients older than 18 years were eligible for study participation if presenting with total occlusions or CTOs with an estimated duration of ≥4 weeks, evidence of ischemia and viability in the territory of the occlusion, and reference diameter of the target vessel between 2.25 and 4.0 mm. The most important exclusion criteria were total occlusions of venous or arterial bypass grafts and in-stent occlusions. The randomization procedure was initiated after successful wire passage with successful pre-dilation of the lesion.
Randomization was performed using an interactive Web-based randomization system.
Patients and referring physicians were blinded to the assigned treatment group.
Definitions
Total coronary occlusion (TCO) was defined as the absence of antegrade flow of contrast distal to the occlusion (TIMI [Thrombolysis In Myocardial Infarction] flow grade 0) or minimal antegrade flow of contrast distal to the occlusion TIMI flow grade 1 in the presence of bridging collateral vessels. The duration of the occlusion was estimated to be ≥4 weeks on the basis of clinical and/or angiographic information. CTO was defined as TCO with an estimated duration of ≥3 months. Procedural success was defined as <30% residual stenosis on visual assessment and TIMI flow grade 3.
Procedure
The procedure was performed by single or double access site from the femoral and/or radial artery with standard coronary catheterization techniques. All patients received dual antiplatelet therapy prior to the procedure or triple therapy in case of indication for oral anticoagulation for at least 12 months according to guidelines of the European Society of Cardiology for stable coronary disease or acute coronary syndromes. Angiographic follow-up was mandated at nine months. Operators were instructed to use fractional flow reserve if they observed intermediate target vessel stenosis <70% with or without angina or >70% in the absence of angina during follow-up angiography.
Quantitative coronary analysis
All coronary angiograms were assessed offline in an independent angiographic core labo- at nine-month follow-up. Binary in-stent restenosis was defined as ≥50% diameter stenosis within the stent. In-segment binary restenosis was defined as ≥50% diameter stenosis located in the stent and/or at the 5 mm proximal or 5 mm distal edge. Reocclusion was defined as recurrent total occlusion at the previous angioplasty site.
Clinical follow-up
An independent clinical event committee adjudicated all clinical endpoints. Clinical follow-up was obtained during hospital stay and at one, six, nine, and 12 months. The vital status of patients was checked in the national population registry (Dutch Central Bureau of Statistics) if they were lost to follow-up or withdrew informed consent. Percutaneous or surgical revascularization was clinically driven if stenosis of the treated lesion was ≥50% of the luminal diameter on the basis of quantitative coronary angiography in the presence of ischemic signs and/or symptoms or if there was diameter stenosis ≥70% irrespective of the presence or absence of ischemic signs or symptoms. Death, myocardial infarction (defined as the presence of new significant Q waves or an elevation of creatine kinase or its MB isoenzyme to at least twice the upper reference limit) and clinically driven target lesion revascularization (defined as revascularization due to a stenosis within a 5-mm border proximal or distal to the stent) were recorded as major adverse cardiac events. Other secondary clinical endpoints included clinically driven target vessel revascularization (defined as revascularization in the entire coronary vessel proximal and distal of the target lesion, including revascularization in side branches), target vessel failure (a composite of cardiac death, myocardial infarction, and clinically driven target vessel revascularization) and stent thrombosis. Finally, the occurrence of angina was recorded using the Canadian Cardiovascular Society (CCS) grading of angina.
Endpoints
The primary noninferiority endpoint was in-segment late lumen loss on nine-month angiography assessed using quantitative coronary analysis. Secondary angiographic endpoints included in-stent late lumen loss, MLD, in-stent and in-segment percentage of diameter stenosis, binary restenosis, and reocclusions at nine months. Secondary individual and composite clinical endpoints were clinically indicated target lesion revascularization or target vessel revascularization, myocardial infarction, death (cardiac and noncardiac), stent thrombosis, target vessel failure, and major adverse cardiac events.
Statistical analysis
In the study design, we hypothesized that the angiographic outcome of the hybrid SES was noninferior that of to the EES in successfully recanalized TCOs and CTOs. The noninferiority margin was set at a conventional level of 0.2 mm. The expected late lumen loss was 0.16 mm for both groups, with a standard deviation of 0.55 mm. 14, 15 The null hypothesis would be rejected if the upper boundary of the 95% confidence interval of the observed difference in in-segment late lumen loss exceeded the noninferiority margin.
The power of the study was >85%, with an alfa level of 5% and 140 patients per group.
A total of 165 patients per group were randomized to account for 20% loss in follow-up angiography. The primary and secondary endpoints were analyzed by intention-to-treat. The Westlake-Schuirmann test (1-sided) was used for the primary noninferiority endpoint. For other secondary clinical and angiographic endpoints, the 2-sample Student t test (2-sided) was used to compare continuous variables and the Fisher exact test to compare binary and categorical outcomes. Cumulative incidence of clinical events was analyzed using the Kaplan-Meier method and compared between treatment groups using the log-rank test. All analyses were performed using R version 3.3 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Enrollment and randomization
An estimated 713 subjects were screened, resulting in 330 randomized patients equally divided between the hybrid SES and EES groups (Figure 1) . Objection to follow-up angiography (22.7%) and failure of wire crossing during the recanalization attempt (30.7%) were the main reasons for screening and enrollment exclusion. Three fault inclusions were observed in the EES group after randomization. Two subjects were randomized with in-stent CTO. One patient was incorrectly randomized after successful reopening of the proximal CTO and failure of recanalization of the distal occlusion in a misjudged tandem CTO in the target vessel. Notwithstanding these exclusions, all subjects were included in the intention-to-treat analysis. 
Baseline clinical, procedural characteristics, and outcomes
Baseline clinical and procedural characteristics were evenly distributed between both groups except for mean J-CTO score (1.8 ± 1.1 vs. 2.0 ± 1.1; p = 0.03; SES vs. EES). Results are shown in Tables 1 and 2. The mean age of the participants was 62 years, with an estimated duration of occlusion ≥3 months (CTO) of 95.2% with SES and 89.7% with EES (p = 0.09) and a mean occlusion length of 20.9 ± 14.5 mm with SES and 20.4 ± 12.4 mm with EES (p = 0.74). The majority of procedures were performed with single-catheter access (70%) from either the radial or the femoral artery. Dual-catheter assess (30%) with the retrograde approach as the primary strategy was performed in 14% of all cases. The average number of implanted stents was 2.1 ± 1.06 versus 2.0 ± 0.96, with a mean total stent length of 52.3 ± 26.6 mm versus 52.4 ± 28.1 mm, for SES versus EES. Periprocedural complications are demonstrated in Table 3 . Two patients in the SES group needed rescue pericardiocentesis. Donor artery dissection, caused by the contralateral catheter in retrograde procedures requiring PCI, was observed in 1 patient in each treatment arm. Untreated dissections in the distal coronary bed of the target vessel occurred in 5 subjects, evenly distributed between both groups. Post-procedural success was 98.8% in both groups. TIMI flow grade 0 was observed after failed recanalization in the EES group.
One patient in each group showed TIMI flow grade 2 caused by untreated dissections in the distal coronary bed without repeated revascularization at follow-up. One patient demonstrated TIMI flow grade 2 with SES after using the limited antegrade dissection re-entry technique requiring clinical target lesion revascularization during follow-up.
Other patients treated with antegrade dissection re-entry technique were free of repeated revascularizations during follow-up. 0.83 Values are mean ± standard deviation and counts (%); *only troponine and no creatine kinase or mb iso-enzym above the upper 99% reference limit; ** Including stopped <6 weeks; ACS, Acute coronary syndrome; AP, angina pectoris; CABG, Coronary artery bypass graft; CT, computer tomography; EES, everolimus-eluting stent; GFR, glomerular filtration ratio; MI, myocardial infarction; MRI, magnetic resonance imaging; PCI, percutaneous coronary intervention; SES, hybrid sirolimus-eluting stents; TLR, target lesion revascularization. Failed recanalization TIMI flow 0 0 1
Minor stroke 1 1
Vascular intervention 0 1
Values are n. Abbreviations as in Table 1 . and 2
Angiographic outcomes
All angiographic end-points are shown in Table 4 and Figure 2 . At nine months, follow-up angiography was available in 281 of 330 patients (85%). There were no significant differences in baseline characteristics between patients with and those without angiographic follow-up at nine months ( Table 1 ). In-segment late lumen loss was 0.13 ±0.63mm in the SES group and 0.02 ± 0.47mmin the EES group (p = 0.08, 2-sided). The observed difference in in-segment late lumen loss was 0.11 mm (95% confidence interval: 0.01 to 0.25 mm). The upper limit of the 95% confidence interval exceeded the noninferiority margin of 0.20 mm. Consequently, the powered noninferiority endpoint was not met for hybrid SES compared with EES (p noninferiority = 0.11, 1-sided). Post hoc analysis demonstrated non-inferiority of the secondary endpoint, in-stent late lumen loss (0.12 ± 0.59 mm vs.
0.07 ± 0.46 mm; p = 0.52, 2-sided; 95% confidence interval: 0.08 to 0.16 mm; p noninferiority = 0.006, 1-sided) with SES and EES, if the noninferiority assumptions of the primary endpoint were applied. The secondary angiographic endpoints (in-stent late lumen loss, in-stent and in-segment MLD, and in-stent and in-segment diameter stenosis) were comparable between SES and EES. The rates of in-stent and in-segment binary restenosis were significantly higher with SES compared with EES (8.0% vs. 2.1%; p = 0.028), with comparable rates of reocclusion (1.4% vs. 2.2%; p = 0.68). All nonocclusive binary restenoses were classified as focal (type Ic). 12 The occurrence of binary restenosis on the previously occluded site was 4.4% versus 2.1% (p = 0.50) with SES and EES. Post hoc sensitivity analysis (Figure 1 ) of baseline characteristics (occlusion duration ≥3 months, symptomatic CCS score ≥III at baseline, post-dilation, and dichotomous stent length ≤30 or >30 mm) demonstrated no interaction with the primary endpoint, in-segment late lumen loss, between the treatment groups. Values are mean ± standard deviation (SD), percentages ± SD and counts (%); *Mehran's in-stent restenosis lesion classification; RVD, reference vessel diameter; other abbreviations as in Table 1 .
Clinical follow-up
Clinical follow-up at 12 months was available in 99% of all subjects (Figure 1) . Two subjects were lost to follow-up, and 1 subject withdrew consent. Of those, 2 subjects were alive at 12 months, confirmed in the national population registry, and 1 subject remained lost to follow-up beyond 9 months because of emigration. All results on angina grading by CCS score at baseline and 12 months and individual and composite clinical events at 12 months are shown in Table 5 . Clinically indicated target lesion and target vessel revascularization, target vessel failure, and major adverse cardiac events were comparable between both groups. Two subjects in the SES group underwent nonclinical target lesion revascularization with balloon angioplasty after observing severe stent strut malapposition with optical coherence tomography at 9 months. There was only 1 probable or definite stent thrombosis in each stent group (0.7% vs. 0.7%; p = 1.00). Angina graded by CCS score was significantly reduced in each treatment arm from the index procedure to 12-month follow-up (p < 0.001 for both), with no difference between both groups (p = 0.77 and p = 0.60).
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Figure 2 In-segment late lumen loss
The mean difference in late lumen loss for the primary endpoint, in-segment late lumen loss, and post hoc analysis of in-stent late lumen loss assessed for noninferiority (A), cumulative frequency (percentage) of in-segment late lumen loss (B), binary in-segment restenosis (percentage) at 9-month follow-up angiography (C), and cumulative frequency (percentage) of in-stent late lumen loss (D) between sirolimus-eluting stents (SES) and everolimus-eluting stents (EES) in patients with successfully recanalized chronic total occlusions.
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Figure 2 (Continued)
Discussion
In this randomized, prospective, multicenter, single-blind study, we investigated the angiographic and clinical outcomes of hybrid ultrathin-strut SES with biodegradable polymer compared with thin-strut EES with durable polymer in CTOs. The major findings were as follows: the noninferiority endpoint of in-segment late lumen loss was not met for SES versus EES, the rate of binary restenosis was significantly higher with SES versus EES, and clinical endpoints and angina relief were comparable between the groups.
The novel design of the hybrid SES with ultrathin struts, a silicon diffusion barrier, and biodegradable polymer seems attractive to promote arterial healing, reduce inflammation, and overcome potential risks for hypersensitivity reactions to permanent polymers. Ex vivo flow studies showed strong correlations of reduced thrombogenicity by decreasing strut thickness and application of polymer and drug coatings on bare-metal stents. 16 Together with biodegradable poly-L-lactic acid polymer, which demonstrated reduced inflammation scores and neointimal growth compared with permanent polymers, the improved design of SES seems the next logical step to reduce restenosis and stent thrombosis in CTOs. 17 We chose the most reputable stent device, the EES (Xience), as a comparator to challenge the novel Orsiro stent in this complex lesion subset. The EES showed robust evidence of efficacy and safety compared with first-generation DES in all type of coronary lesions, including CTOs. 7, [18] [19] [20] Our findings are not in line with earlier presented results from the BIOFLOW-II study. In this study, angiographic noninferiority was demonstrated between SES and EES in simple de novo lesions with no difference of in-stent or in-segment late lumen loss (0.10 ± 0.32 mm vs. 0.11 ± 0.29 mm [p = 0.98, p noninferiority <0.0001] and 0.09 ± 0.35 mm vs. 0.09 ± 0.33 mm [p = 0.86]). Angiographic late lumen loss is a powerful predictor of present or future binary restenosis or clinical revascularizations and is particularly useful in "smaller" trials not powered to assess clinical endpoints. 21 Our results showed that the predetermined prima- EES). This could be caused partially by routine angiographic follow-up and the difference in lesion complexity, but these findings merit longer-term clinical follow-up.
Quality of life was measured using the CCS score, demonstrating significant angina reduction after the index procedure with either study stent, with no difference between both stent groups. Successful recanalization of CTOs reduces ischemic burden, favors left ventricular function, and relieves angina in symptomatic patients. 27 Quality of health is gaining importance in interventional cardiology beyond just a reduction in clinical events. In this study, angina was registered with the easily acquired CCS score, which has shown reasonable correlation with the more sophisticated seven-domain Seattle Angina Questionnaire in stable coronary artery disease. 28
Study limitations
Our definition of TCO and inclusion criterion for study participation were different from the accepted definition of CTO. Nevertheless, more than 92% of the included patients satisfied the accepted CTO definition of estimated duration equal to or more than three months with TIMI flow grade 0. This study represented a population of "real-world" CTO practice. 29 However, the results should be cautiously extrapolated to patients with CTOs, presenting with a higher prevalence of comorbidities and more complex lesion characteristics, requiring a higher rate of advanced recanalization techniques embraced in the state-of-the-art hybrid algorithm. Furthermore, there was a difference in CTO complexity, expressed by the J-CTO score between the groups. However, bias of the overall angiographic and clinical results seems unlikely, with lower J-CTO scores in the SES group. Although operators were instructed to perform high-pressure post-dilation, the reported rate of post-dilations was low (35%). In contrast, the average maximal balloon or stent pressure was well above the nominal stent pressure ( 
Conclusions
This prospective, multicenter randomized trial failed to show noninferiority of hybrid ultrathin-strut SES with biodegradable polymer relative to thin-strut EES with durable polymer in terms of in-segment late lumen loss in successfully recanalized CTOs. Furthermore, the rate of binary restenosis was statistically significantly higher with SES.
